ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Correspondence
Revised

Matching target dose to target organ

[version 2; peer review: 2 approved]
PUBLISHED 30 Mar 2017
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

In vitro assays have become a mainstay of modern approaches to toxicology with the promise of replacing or reducing the number of in vivo tests required to establish benchmark doses, as well as increasing mechanistic understanding. However, matching target dose to target organ is an often overlooked aspect of in vitro assays, and the calibration of in vitro exposure against in vivo benchmark doses is often ignored, inadvertently or otherwise.  An example of this was recently published in Environmental Health Perspectives by Wagner et al (2016), where neural stems cells were used to model the molecular toxicity of lead.  On closer examination of the in vitro work, the doses used in media reflected in vivo lead doses that would be at the highest end of lead toxicity, perhaps even lethal.  Here we discuss the doses used and suggest more realistic doses for future work with stem cells or other neuronal cell lines.

Keywords

In vitro, lead, in vivo, dose, stem cells.

Revised Amendments from Version 1

The content of the article has been modified in response to the reviewers, and further we have separately included our response to the reviewer's of our correspondence article.

See the authors' detailed response to the review by Donald Smith
See the authors' detailed response to the review by Mir Ahamed Hossain

A recent article by Wagner et al. reported the involvement of the anti-oxidant Nrf2 transcription factor signaling pathway in the toxicity of lead using neural stem cells in an in vitro model of neuronal differentiation1. While this work was completed in a similar way to other studies involving in vitro lead exposure, the work avoids a critical, often neglected issue of what constitutes a relevant physiological dose in vitro. The assumption that the selected dose of 1 µM (or 20.7 µg/dL) for neuronal stem cell exposure was “4 times the CDC levels of concern (LOC) for blood lead (5 µg/dL) and is within the range of exposed populations” requires further examination. Since the in vitro exposure was completed in media (the equivalent of plasma or serum) and not in whole blood, the assumption that the in vitro lead level would be equivalent to that found in whole blood of lead-exposed humans is somewhat inaccurate. Lead in serum (or plasma) represents only a fraction (~1%) of the level found in whole blood2,3, with the major fraction of lead bound inside erythrocytes4. For arguments sake, if the proportion of lead used in this study was 1% of that in whole blood, the extrapolated blood lead value would be approximately 2073 µg/dL, a level over 400 times the CDC LOC, and one that would be acutely toxic and perhaps lethal.

Another study, which was cited by Wagner et al.1, showed that measurable effects in stem cells in vitro could occur at doses as low as 0.4 µM5; this dose would represent a blood lead level of 829 µg/dL, using the same assumptions as above. In a study by Chan et al., the lowest dose of 1 µM lead used in a study of newborn rat neuronal stem cells would represent 20.73 µg/L in serum and a systemic blood lead level of about 2073 µg/dL6. Other studies examining the toxicity of lead in cell cultures have also failed to adequately match the in vitro doses79 with those found in vivo, by taking account of the well documented relationship between plasma and whole blood lead values. More importantly, with measurable effects only beginning at greater than 10 µM for some studies6,9, could these data suggest the alternative conclusion - that neuronal cells in vivo are more resistant to toxic insult by lead, at least in the short term?

What is clear is that at current blood lead levels in the US population, serum or plasma levels will represent a very low fraction of those values and in vitro work could more realistically model neurological effects in humans if target doses were better matched to target organ. Thus, the model of exposure proposed by Wagner et al. and other in vitro work demonstrating toxic effects of lead59 may be more appropriate for high acute exposures. More realistically, to ensure that doses used for in vitro assays are complimentary to a target in vivo blood lead level of 20 µg/dL, exposure to cells in vitro should correspond to ~1% of the cited blood lead value, or a dose of 0.2 µg/dL (0.01 µM). At the current CDC 5 µg/dL LOC for children, the in vitro dose would become 0.05 µg/dL (0.002 µM); a dose that would present difficulties to laboratories that cannot eliminate background levels from residual lead on glassware and other sources of possible contamination or confounding of the reported data. Background contamination in controls would mean requiring higher exposure doses to demonstrate an effect, essentially making the assays less sensitive.

In the study by Wagner et al.1, much of this may have been considered by the authors, and key assumptions may have been made; however, the question still remains whether the upregulation of genes in the Nrf2-mediated anti-oxidative stress pathway would have been observed if a more physiologically relevant dose of 0.2 µg/dL (0.1 µM) in the media (i.e., representing a blood lead level of 20 µg/dL) had been used.

How does lead in plasma compare to lead in cerebrospinal fluid? Presumably the plasma fraction contains the lead moiety that interacts with molecular targets in the brain. Evidence shows that lead in cerebrospinal fluid is 50% of that in serum2, indicating that the assumptions made here are consistent with target doses of lead in the brain being much closer in value to plasma than to whole blood lead. We did not account of the evidence that the proportion of lead in plasma increases with increasing blood lead value3,4 – which could affect our upward extrapolations from putative plasma values of 20 µg/dL to whole blood lead levels of 2073 µg/dL – but it should not affect extrapolating downward to plasma lead from a starting blood lead of 20 µg/dL as the relationship between whole blood and plasma lead seems to be linear in that region3. However, even if we used a value of 5% lead in plasma the extrapolated blood lead for the Wagner et al. study would turn out to be 20-fold the plasma which is 400 µg/dL.

Our article raises questions about what a relevant in vitro lead dose should be when it is contextually related to in vivo blood lead values. A scan of the literature for this article has shown that there are a significant number of in vitro publications using lead that lack (or even misinterpret) context with whole blood lead levels, thereby identifying molecular effects that may not have relevance to current national blood lead values. We propose that matching target dose to target organ should be more carefully considered with future in vitro work.

Disclaimer

The views expressed in this article are those of the author(s) and do not necessarily reflect the official policy of the Department of Defense, Department of the Army, U.S. Army Medical Department or the U.S.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 29 Nov 2016
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Bannon DI and Williams MA. Matching target dose to target organ [version 2; peer review: 2 approved]. F1000Research 2017, 5:2785 (https://doi.org/10.12688/f1000research.10055.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 29 Nov 2016
Views
15
Cite
Reviewer Report 26 Jan 2017
Donald Smith, Microbiology and Environmental Toxicology, University of California Santa Cruz, Santa Cruz, CA, USA 
Approved
VIEWS 15
This commentary is well written, very well justified, and timely. While there are countless published papers on the myriad effects of lead in biological systems, the consideration of dose extrapolation from in vitro to in vivo studies and their relationships ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Smith D. Reviewer Report For: Matching target dose to target organ [version 2; peer review: 2 approved]. F1000Research 2017, 5:2785 (https://doi.org/10.5256/f1000research.10834.r19115)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response (F1000Research Advisory Board Member) 30 Mar 2017
    Mark A Williams, Army Public Health Center, USA
    30 Mar 2017
    Author Response F1000Research Advisory Board Member
    Reviewer 2.   We thank reviewer #2 for knowledgeable and helpful comments on our article. Here are our responses to specific comments. 
     
    Comment 1.  This point is well made – ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response (F1000Research Advisory Board Member) 30 Mar 2017
    Mark A Williams, Army Public Health Center, USA
    30 Mar 2017
    Author Response F1000Research Advisory Board Member
    Reviewer 2.   We thank reviewer #2 for knowledgeable and helpful comments on our article. Here are our responses to specific comments. 
     
    Comment 1.  This point is well made – ... Continue reading
Views
17
Cite
Reviewer Report 18 Jan 2017
Mir Ahamed Hossain, Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, USA 
Approved
VIEWS 17
In vitro assays have become a mainstay of modern approaches to toxicology with a high promise of understanding the underlying mechanisms of toxicity. The results reported by Wagner et al., (2016) in the August 26 issue of the Environmental Health ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Hossain MA. Reviewer Report For: Matching target dose to target organ [version 2; peer review: 2 approved]. F1000Research 2017, 5:2785 (https://doi.org/10.5256/f1000research.10834.r19455)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response (F1000Research Advisory Board Member) 30 Mar 2017
    Mark A Williams, Army Public Health Center, USA
    30 Mar 2017
    Author Response F1000Research Advisory Board Member
    Reviewer 1.  We thank reviewer #1 for helpful comments on our article. We address some specific aspects below.
     
    The reviewer agreed with our principle argument, but goes on to ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response (F1000Research Advisory Board Member) 30 Mar 2017
    Mark A Williams, Army Public Health Center, USA
    30 Mar 2017
    Author Response F1000Research Advisory Board Member
    Reviewer 1.  We thank reviewer #1 for helpful comments on our article. We address some specific aspects below.
     
    The reviewer agreed with our principle argument, but goes on to ... Continue reading

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 29 Nov 2016
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.